Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

US Anticoagulation Therapy Market - Projected to Reach USD 27.8 Billion by 2022 - Research and Markets

Research and Markets
Posted on: 10 Nov 17

The "US Anticoagulation Therapy Market - Forecast to 2022" report has been added to Research and Markets' offering.

The US anticoagulation therapy market is projected to reach USD 27.83 billion by 2022 from an estimated USD 18.49 billion in 2017, at a CAGR of 8.5%. The US anticoagulation therapy market is segmented into products (anticoagulation drugs, PT/INR testing devices) and anticoagulation clinics.

The growth of the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs). On the other hand, the high cost of NOACs and requirement of significant investments in the development of anticoagulation drugs are the major factors restraining the growth of this market. In addition, the growth of the anticoagulation clinics market is primarily driven by the increasing prevalence of cardiovascular diseases & blood disorders, high level of medication adherence associated with clinics, and rising aging population.

The anticoagulation therapy market for drugs is categorized into NOACs, warfarin (VKA), and other drugs. The NOACs segment is expected to grow at the highest CAGR during the forecast period. Due to the better safety and efficacy of NOACs, as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs. In addition, key market players such as Portola Pharmaceuticals (received the FDA approval for its NOAC-Betrixaban in July 2017) are focusing on the development of NOACs in order to capitalize on the growth opportunities presented by this shift in market dynamics. Consequently, many other companies are also expected to focus on developing more safe and efficient NOACs in the coming years; this will ensure the continued growth of this segment.

Companies Mentioned

  • Abbott Laboratories
  • Alere Inc.
  • Bristol-Myers Squibb Company
  • C. H. Boehringer Sohn AG & Co. Kg
  • Coagusense, Inc.
  • Daiichi Sankyo Company, Limited
  • Johnson & Johnson
  • Pfizer, Inc.
  • Portola Pharmaceuticals, Inc.
  • Siemens AG

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Market Overview

4 Market Insights

5 US Anticoagulation Therapy (Products) Market

6 US Anticoagulation Therapy Market for Clinics

7 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/h7phmb/us

View source version on businesswire.com: http://www.businesswire.com/news/home/20171110005248/en/

Business Wire
www.businesswire.com

Last updated on: 10/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.